Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial
- PMID: 36806843
- PMCID: PMC10069850
- DOI: 10.1093/humrep/dead029
Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial
Abstract
Study question: In women with threatened miscarriage, does progesterone supplementation until the completion of the first trimester of pregnancy increase the probability of live birth?
Summary answer: In women with threatened miscarriage, 400 mg vaginal progesterone nightly, from onset of bleeding until 12 weeks, did not increase live birth rates.
What is known already: Limited evidence has indicated that vaginal micronized progesterone may make little or no difference to the live birth rate when compared with placebo in women with threatened miscarriage. Subgroup analysis of one recent randomized trial reported that in women with bleeding and at least one previous miscarriage, progesterone might be of benefit.
Study design, size, duration: We performed a randomized, double-blinded, placebo-controlled trial between February 2012 and April 2019. Eligible pregnant women under 10 weeks gestation, experiencing a threatened miscarriage as apparent from vaginal bleeding were randomized into two groups in a 1:1 ratio: the intervention group received 400 mg progesterone as vaginal pessaries, the control group received placebo vaginal pessaries, both until 12 weeks gestation. The primary endpoint was live birth. We planned to randomize 386 women (193 per group). The study was stopped at a planned interim analysis for futility after randomization of 278 women.
Participants/materials, setting, methods: This trial was conducted at the Mater Mothers' Hospital, a tertiary centre for maternity care in South Brisbane, Queensland, Australia. We randomized 139 women to the intervention group and 139 women to the placebo group. Primary outcome data were available for 136 women in the intervention group and 133 women in the placebo group.
Main results and the role of chance: The live birth rates were 82.4% (112/136) and 84.2% (112/133) in the intervention group and placebo group, respectively (risk ratio (RR) 0.98, 95% CI 0.88 to 1.09; risk difference -0.02, 95% CI -0.11 to 0.07; P = 0.683). Among women with at least one previous miscarriage, live birth rates were 80.6% (54/67) and 84.4% (65/77) (RR 0.95, 95% CI 0.82-1.11; P = 0.550). No significant effect was seen from progesterone in women with two (RR 1.28, 95% CI 0.96-1.72; P = 0.096) or more (RR 0.79, 95% CI 0.53-1.19; P = 0.267) previous miscarriages. Preterm birth rates were 12.9% and 9.3%, respectively (RR 1.38; 95% CI 0.69 to 2.78; P = 0.361). Median birth weight was 3310 vs 3300 g (P = 0.992). There were also no other significant differences in obstetric and perinatal outcomes.
Limitations, reasons for caution: Our study was single centre and did not reach the planned sample size because it was stopped prematurely at an interim analysis.
Wider implications of the findings: We did not find evidence supporting the treatment effect of vaginal progesterone in women with threatened miscarriage. Progesterone in this setting should not be routinely used for threatened miscarriage. The treatment effect in women with threatened miscarriage after previous miscarriages warrants further research.
Study funding/competing interest(s): Mothers' and babies Golden Casket Clinical Fellowship (L.A.M.). Progesterone and placebo pessaries were provided by Perrigo Australia.B.W.J.M. reports grants from NHMRC, personal fees from ObsEva, personal fees from Merck KGaA, personal fees from Guerbet, personal fees from iGenomix, outside the submitted work.
Trial registration number: ACTRN12611000405910.
Trial registration date: 19 April 2011.
Date of first patient’s enrolment: 06 February 2012.
Keywords: early pregnancy; live birth; miscarriage prevention; progesterone; threatened miscarriage.
© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Conflict of interest statement
B.W.J.M. reports grants from NHMRC, personal fees from ObsEva, personal fees from Merck KGaA, personal fees from Guerbet, personal fees from iGenomix, outside the submitted work.
Figures
Similar articles
-
No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis.Hum Reprod Open. 2024 Jan 23;2024(1):hoae004. doi: 10.1093/hropen/hoae004. eCollection 2024. Hum Reprod Open. 2024. PMID: 38344249 Free PMC article. Review.
-
Progestogens for preventing miscarriage: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD013792. doi: 10.1002/14651858.CD013792.pub2. Cochrane Database Syst Rev. 2021. PMID: 33872382 Free PMC article.
-
Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial.Hum Reprod. 2021 Feb 18;36(3):587-595. doi: 10.1093/humrep/deaa327. Hum Reprod. 2021. PMID: 33331637 Clinical Trial.
-
Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT.Health Technol Assess. 2020 Jun;24(33):1-70. doi: 10.3310/hta24330. Health Technol Assess. 2020. PMID: 32609084 Free PMC article. Clinical Trial.
-
Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence.Am J Obstet Gynecol. 2020 Aug;223(2):167-176. doi: 10.1016/j.ajog.2019.12.006. Epub 2020 Jan 31. Am J Obstet Gynecol. 2020. PMID: 32008730 Free PMC article. Review.
Cited by
-
Exploring Progesterone Deficiency in First-Trimester Miscarriage and the Impact of Hormone Therapy on Foetal Development: A Scoping Review.Children (Basel). 2024 Apr 2;11(4):422. doi: 10.3390/children11040422. Children (Basel). 2024. PMID: 38671639 Free PMC article. Review.
-
Progesterone in Pregnancy: Evidence-Based Strategies to Reduce Miscarriage and Enhance Assisted Reproductive Technology.Med Sci Monit. 2024 Mar 8;30:e943400. doi: 10.12659/MSM.943400. Med Sci Monit. 2024. PMID: 38501164 Free PMC article.
-
Can single progesterone concentration predict miscarriage in early pregnant women with threatened miscarriage: a systematic review and meta-analysis.BMC Pregnancy Childbirth. 2024 Feb 13;24(1):133. doi: 10.1186/s12884-024-06303-7. BMC Pregnancy Childbirth. 2024. PMID: 38350926 Free PMC article.
-
Luteal phase support in assisted reproductive technology.Nat Rev Endocrinol. 2024 Mar;20(3):149-167. doi: 10.1038/s41574-023-00921-5. Epub 2023 Dec 18. Nat Rev Endocrinol. 2024. PMID: 38110672 Review.
References
-
- Antony MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP.. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. Psychol Assess 1998;10:176–181.
-
- Arck PC, Rücke M, Rose M, Szekeres-Bartho J, Douglas AJ, Pritsch M, Blois SM, Pincus MK, Bärenstrauch N, Dudenhausen JW. et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 2008;17:101–113. - PubMed
-
- Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ.. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med 2005;159:957–962. - PubMed
-
- Chan DMK, Cheung KW, Ko JKY, Yung SSF, Lai SF, Lam MT, Ng DYT, Lee VCY, Li RHW, Ng EHY.. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial. Hum Reprod 2021;36:587–595. - PubMed
-
- Chong K, Li W, Roberts I, Mol BW.. Making miscarriage matter. Lancet 2021;398:743–744. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous